Biotechnology and Entrepreneurship Research | A Proposed Novel Drug Treatment of Actinic Keratosis



Published
Research Presentation: A Proposed Novel Two-Drug Combination Topical Treatment of Actinic Keratosis
Presented by: Jonathan Taub
Abstract: Actinic keratosis (AK) and cutaneous squamous cell carcinoma (cSCC) incidences have increased exponentially over the last half-century, even as methods of diagnosis and diagnostic definitions themselves remain malleable. An estimated two-thirds of all AK and cSCC patients are over the age of 65, possibly presenting a public health concern. One group of AK and cSCC sufferers that might find themselves with more restricted options in a crowded therapeutic field are immunocompromised patients, particularly patients with transplants. GritBIO proposes a combination of two drugs—miltefosine and carmofur—in a novel composition for topical administration, which would provide the requisite cytotoxicity without the attendant adverse effects on immune cells. This project aims to understand the market, IP constrains, regulatory requirements, and the potential for fast-track designation for this treatment

Learn More:
M.S. in Biotechnology Management and Entrepreneurship Program: bit.ly/3x4gfBQ
Forefront, the Katz School Symposium on Science, Technology, and Health: bit.ly/3OJvh7O
Katz School of Science and Health at Yeshiva University: bit.ly/3PWXngG
Category
Health
Be the first to comment